CA2295035C - Pharmaceutical formulations containing voriconazole - Google Patents
Pharmaceutical formulations containing voriconazole Download PDFInfo
- Publication number
- CA2295035C CA2295035C CA002295035A CA2295035A CA2295035C CA 2295035 C CA2295035 C CA 2295035C CA 002295035 A CA002295035 A CA 002295035A CA 2295035 A CA2295035 A CA 2295035A CA 2295035 C CA2295035 C CA 2295035C
- Authority
- CA
- Canada
- Prior art keywords
- voriconazole
- formulation
- cyclodextrin
- 4so3h
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention provides a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula (I), wherein R1a-g, R2a-g and R3a-g independently represent OH or O(CH2)4SO3H; or a pharmaceutically acceptable salt thereof.
Description
Pharmaceutical formulations containin; voriconazole This invention relates to a new pharmaceutical formulation of voriconazole with a sulphobutylether (3-cyclodextrin.
Voriconazole is disclosed in European Patent Application 0440372 (see Example 7). It has the following structure:
OH
N
~~ ' N
N F ~ N~/N
F
and is useful in the treatment of fungal infections. Voriconazole has a low aqueous solubility (0.2mg/ml @ pH 3), and is not stable in water (an inactive enantiomer is formed from recombination of the retro-aldol products of hydrolysis). Thus, development of an aqueous intravenous formulation with a sufficient shelf life is difficult.
These problems are magnified by the semi-polar nature of the compound (log D = 1.8) which means that it is not generally solubilised by conventional means such as oils, surfactants or water miscible co-solvents.
European Patent Application 0440372 mentions that the compounds disclosed therein may be formulated with cyclodextrin: however, it is now suspected that underivatised or unmetabolised cyclodextrin has toxic effects on the body and so is unsuitable as a pharmaceutical excipient, particularly when administered parenterally.
International Patent Application WO 91/11172 discloses sulphoalkylether cyclodextrin derivatives of formula A.
Voriconazole is disclosed in European Patent Application 0440372 (see Example 7). It has the following structure:
OH
N
~~ ' N
N F ~ N~/N
F
and is useful in the treatment of fungal infections. Voriconazole has a low aqueous solubility (0.2mg/ml @ pH 3), and is not stable in water (an inactive enantiomer is formed from recombination of the retro-aldol products of hydrolysis). Thus, development of an aqueous intravenous formulation with a sufficient shelf life is difficult.
These problems are magnified by the semi-polar nature of the compound (log D = 1.8) which means that it is not generally solubilised by conventional means such as oils, surfactants or water miscible co-solvents.
European Patent Application 0440372 mentions that the compounds disclosed therein may be formulated with cyclodextrin: however, it is now suspected that underivatised or unmetabolised cyclodextrin has toxic effects on the body and so is unsuitable as a pharmaceutical excipient, particularly when administered parenterally.
International Patent Application WO 91/11172 discloses sulphoalkylether cyclodextrin derivatives of formula A.
(A) wherein n is 4, 5 or 6;
R,_9 independently represent O- or O-(C,_6 alkylene)-SO-, provided that at least one of R, and R, is O-(C~_6 alkylene)-SO'; and S,_9 independently represent a pharmaceutically acceptable cation (such as H' or Na').
It has now been found that the solubility of voriconazoIe in water can be increased by molecular encapsulation with sulphoalkylether cyclodextrin derivatives of the type disclosed in International Patent Application WO 91/11172, particularly when n is 5 (a (3-cyciodextrin derivative) and the cyclodextrin ring is substituted by sulphobutyl groups.
Thus, according to the present invention, there is provided a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula I, R'9CH O
z CHZR'a O R39 O ~~
0 RsrRz9 Rza Raa O
R'rCH Rzr Rzb ~ CH R'°
z z 0 R3b O
O R3e Rz~ 0 (I) Rze R3d 2d R~gCHz O R R3~ ~ CHZR' O
CHzR'd wherein R'a-°, R'-''~ and R''a-~ independently represent OH or O(CH,)~SO~H;
provided that at least one of R'a-s represents O(CH,),SO;H;
R,_9 independently represent O- or O-(C,_6 alkylene)-SO-, provided that at least one of R, and R, is O-(C~_6 alkylene)-SO'; and S,_9 independently represent a pharmaceutically acceptable cation (such as H' or Na').
It has now been found that the solubility of voriconazoIe in water can be increased by molecular encapsulation with sulphoalkylether cyclodextrin derivatives of the type disclosed in International Patent Application WO 91/11172, particularly when n is 5 (a (3-cyciodextrin derivative) and the cyclodextrin ring is substituted by sulphobutyl groups.
Thus, according to the present invention, there is provided a pharmaceutical formulation comprising voriconazole, or a pharmaceutically acceptable derivative thereof, and a cyclodextrin derivative of formula I, R'9CH O
z CHZR'a O R39 O ~~
0 RsrRz9 Rza Raa O
R'rCH Rzr Rzb ~ CH R'°
z z 0 R3b O
O R3e Rz~ 0 (I) Rze R3d 2d R~gCHz O R R3~ ~ CHZR' O
CHzR'd wherein R'a-°, R'-''~ and R''a-~ independently represent OH or O(CH,)~SO~H;
provided that at least one of R'a-s represents O(CH,),SO;H;
or a pharmaceutically acceptable salt thereof.
Pharmaceutically acceptable salts of particular interest are salts of the O(CH,)aS03H
' groups, for example alkali metal salts, such as sodium salts.
Preferably, the average number of O(CH,),SO~H groups per molecule of formula I
is in the range 6.1-6.9, for example 6.5. This enhances molecular encapsulation resulting in enhanced voriconazole solubility. This effect would not be anticipated because increasing the degree of substitution increases steric hindrance around the cavity of the cyclodextrin and would be expected to reduce complexation efficiency.
It is preferred that each O(CH,)~SO;H present is in the form of an alkali metal salt (such as the sodium salt). This enhances the affinity of the molecule for voriconazole, which is unexpected because voriconazole is not charged.
Preferably, the formulation is for parenteral administration, for example, i.v.
administration.
The aqueous stability of the voriconazole-cyclodextrin derivative complex is further enhanced by lyophilisation (freeze-drying). The cyclodextrin derivatives used in formulations according to the invention enable the finished lyophilised product to accommodate high levels of moisture (up to 3.0%) without a detrimental effect on stability.
Furthermore, the use of such cyclodextrin derivatives controls and minimises the formation of the inactive enantiomer of voriconazole.
Generally, in aqueous intravenous and intramuscular formulations according to the invention, the voriconazole will be present at a concentration of from ~ m~/ml to SO
mg/ml, for example 10 mg/ml to 30 mg/ml. The cvclodextrin derivative of formula I will be present in a molar ratio of voriconazole:cyclodextrin derivative of from 1:1 to 1:10. for example 1:2 to 1:7, in particular 1:2 to 1:3. The formulations may be lyophilised (freeze dried) for storage prior to use, and made up with water when required.
Pharmaceutically acceptable salts of particular interest are salts of the O(CH,)aS03H
' groups, for example alkali metal salts, such as sodium salts.
Preferably, the average number of O(CH,),SO~H groups per molecule of formula I
is in the range 6.1-6.9, for example 6.5. This enhances molecular encapsulation resulting in enhanced voriconazole solubility. This effect would not be anticipated because increasing the degree of substitution increases steric hindrance around the cavity of the cyclodextrin and would be expected to reduce complexation efficiency.
It is preferred that each O(CH,)~SO;H present is in the form of an alkali metal salt (such as the sodium salt). This enhances the affinity of the molecule for voriconazole, which is unexpected because voriconazole is not charged.
Preferably, the formulation is for parenteral administration, for example, i.v.
administration.
The aqueous stability of the voriconazole-cyclodextrin derivative complex is further enhanced by lyophilisation (freeze-drying). The cyclodextrin derivatives used in formulations according to the invention enable the finished lyophilised product to accommodate high levels of moisture (up to 3.0%) without a detrimental effect on stability.
Furthermore, the use of such cyclodextrin derivatives controls and minimises the formation of the inactive enantiomer of voriconazole.
Generally, in aqueous intravenous and intramuscular formulations according to the invention, the voriconazole will be present at a concentration of from ~ m~/ml to SO
mg/ml, for example 10 mg/ml to 30 mg/ml. The cvclodextrin derivative of formula I will be present in a molar ratio of voriconazole:cyclodextrin derivative of from 1:1 to 1:10. for example 1:2 to 1:7, in particular 1:2 to 1:3. The formulations may be lyophilised (freeze dried) for storage prior to use, and made up with water when required.
In the following example, the sulphobutylether (3-cyclodextrin has an average sulphobutylether substitution of 6.5 per cyclodextrin molecule, and each sulphobutylether unit is present as its sodium salt.
Example 1 , i.v. formulation of voriconazole In red diem Specification m.
Voriconazole Pfizer 10.000 Sulphobutylether (3-cyclodextrin Pfizer 160.000 Water for injections Ph. Eur. to 1.000 ml Total 1.000 ml Method:
I S 1. With constant stirring, add the sulphobutylether ~i cyclodextrin (SBECD) to 80% of the final volume of water for injections, and continue to stir until all the SBECD has dissolved.
2. Add the voriconazole and dissolve with stirnng.
3. Make the solution up to volume with water for injections.
4. Filter the resulting solution through a sterile 0.2 mm nylon filter into a sterile container.
Example 1 , i.v. formulation of voriconazole In red diem Specification m.
Voriconazole Pfizer 10.000 Sulphobutylether (3-cyclodextrin Pfizer 160.000 Water for injections Ph. Eur. to 1.000 ml Total 1.000 ml Method:
I S 1. With constant stirring, add the sulphobutylether ~i cyclodextrin (SBECD) to 80% of the final volume of water for injections, and continue to stir until all the SBECD has dissolved.
2. Add the voriconazole and dissolve with stirnng.
3. Make the solution up to volume with water for injections.
4. Filter the resulting solution through a sterile 0.2 mm nylon filter into a sterile container.
5. Fill 20 ml volumes into sterile freeze drying vials and stopper.
Lyophilise.
Lyophilise.
Claims (7)
1. A pharmaceutical formulation comprising voriconazole and a cyclodextrin derivative of formula I, wherein:
R1a-g, R2a-g and R3a-g independently represent OH or O(CH2)4SO3H;
provided that at least one of R1a-g represents O(CH2)4SO3H;
or a pharmaceutically acceptable salt thereof.
R1a-g, R2a-g and R3a-g independently represent OH or O(CH2)4SO3H;
provided that at least one of R1a-g represents O(CH2)4SO3H;
or a pharmaceutically acceptable salt thereof.
2. The formulation as claimed in claim 1, wherein the cyclodextrin derivative has an average number of O(CH2)4SO3H
groups per molecule of formula I in the range 6.1-6.9.
groups per molecule of formula I in the range 6.1-6.9.
3. The formulation as claimed in claim 1 or claim 2, wherein each O(CH2)4SO3H present is in the form of an alkali metal salt.
4. The formulation as claimed in any one of claims 1 to 3, which is adapted for parenteral administration.
5. The formulation as claimed in any one of claims 1 to 4, wherein the cyclodextrin derivative of formula I is present in a molar ratio of voriconazole:cyclodextrin derivative of from 1:1 to 1:10.
6. The formulation as claimed in any one of claims 1 to 5, which is a solution in water.
7. The formulation as claimed in any one of claims 1 to 5, which has been lyophilised.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9713149.4A GB9713149D0 (en) | 1997-06-21 | 1997-06-21 | Pharmaceutical formulations |
| GB9713149.4 | 1997-06-21 | ||
| PCT/EP1998/003477 WO1998058677A1 (en) | 1997-06-21 | 1998-06-02 | Pharmaceutical formulations containing voriconazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2295035A1 CA2295035A1 (en) | 1998-12-30 |
| CA2295035C true CA2295035C (en) | 2005-04-19 |
Family
ID=10814734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002295035A Expired - Lifetime CA2295035C (en) | 1997-06-21 | 1998-06-02 | Pharmaceutical formulations containing voriconazole |
Country Status (48)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9818258D0 (en) * | 1998-08-21 | 1998-10-14 | Pfizer Ltd | Antifungal compositions |
| PE20020300A1 (en) | 2000-08-22 | 2002-05-10 | Pharmacia Corp | COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD |
| PE20020578A1 (en) | 2000-10-10 | 2002-08-14 | Upjohn Co | A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS |
| PL212428B1 (en) * | 2002-08-20 | 2012-09-28 | Bristol Myers Squibb Co | Aripiprazole complex formulation and method |
| GB0327390D0 (en) * | 2003-11-25 | 2003-12-31 | Pfizer Ltd | Pharmaceutical formulations |
| CN1889943A (en) * | 2003-12-08 | 2007-01-03 | 美国亚利桑那大学董事会 | Synergistic anti-cancer compounds |
| EP2803357B1 (en) | 2004-06-25 | 2020-11-18 | The Johns-Hopkins University | Angiogenesis inhibitors |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| US20070082870A1 (en) * | 2005-10-11 | 2007-04-12 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and antifungal azole compounds |
| AR061889A1 (en) | 2006-07-13 | 2008-10-01 | Medichem Sa | IMPROVED PROCESS FOR THE PREPARATION OF VORICONAZOL |
| CN1919846B (en) * | 2006-09-14 | 2013-01-02 | 大道隆达（北京）医药科技发展有限公司 | Novel oriented synthesis method of voriconazole, medicinal salt and intermediate thereof |
| BG1110U1 (en) * | 2007-06-19 | 2008-09-30 | Рудолф ПОДЛИПСКИ | Heater for express local heating of water |
| EP2018866A1 (en) * | 2007-07-27 | 2009-01-28 | Sandoz AG | Pharmaceutical compositions containing voriconazole |
| US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
| WO2009137611A2 (en) * | 2008-05-06 | 2009-11-12 | Board Of Regents, The University Of Texas System | Treatment of pulmonary fungal infection with voriconazole via inhalation |
| US20110105448A1 (en) * | 2008-06-06 | 2011-05-05 | Glenmark Pharmaceuticals Limited | Stable Topical Formulation Comprising Voriconazole |
| CN101390825B (en) * | 2008-10-01 | 2010-12-29 | 山东省眼科研究所 | Intra-ocular release system of voriconazole |
| EP2349313A4 (en) | 2008-10-21 | 2012-08-29 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones |
| CN101444510B (en) * | 2008-12-31 | 2011-03-09 | 南京卡文迪许生物工程技术有限公司 | Pharmaceutical preparation containing voriconazole and preparation method thereof |
| WO2011020605A1 (en) | 2009-08-19 | 2011-02-24 | Ratiopharm Gmbh | Process for the production of coevaporates and complexes comprising voriconazole and cyclodextrin |
| WO2011064558A2 (en) | 2009-11-30 | 2011-06-03 | Cipla Limited | Pharmaceutical composition |
| KR101834024B1 (en) | 2010-06-29 | 2018-03-02 | 머크 샤프 앤드 돔 코포레이션 | Posaconazole intravenous solution formulations stabilized by substituted beta-cyclodextrin |
| EP2409699B1 (en) * | 2010-07-23 | 2014-04-30 | Combino Pharm, S.L. | Stable compositions of voriconazole |
| CN102058519B (en) * | 2010-11-19 | 2013-01-02 | 苏州特瑞药业有限公司 | Voriconazole slow-release suppository and preparation method thereof |
| WO2012171561A1 (en) | 2011-06-15 | 2012-12-20 | Synthon Bv | Stabilized voriconazole composition |
| EP2561863A1 (en) | 2011-08-22 | 2013-02-27 | Farmaprojects, S.A.U. | Pharmaceutical compositions comprising voriconazole |
| US20150030668A1 (en) * | 2012-01-05 | 2015-01-29 | Frederick Timothy Guilford | Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions |
| US8853248B2 (en) | 2012-04-05 | 2014-10-07 | Hubert Maehr | (1,2,3-triazolyl)sulfonyl derivatives |
| CN104411334A (en) | 2012-05-08 | 2015-03-11 | 欧尼斯治疗公司 | Cylodextrin complexation methods for formulating peptide proteasome inhibitors |
| KR20150028241A (en) | 2012-05-11 | 2015-03-13 | 시플라 리미티드 | Pharmaceutical composition |
| EP2943224B1 (en) | 2013-01-11 | 2020-01-01 | Xellia Pharmaceuticals ApS | Voriconazole inclusion complexes |
| US20140275122A1 (en) | 2013-03-14 | 2014-09-18 | Fresenius Kabi Usa, Llc | Voriconazole Formulations |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| CN103690968A (en) * | 2013-11-21 | 2014-04-02 | 石药集团中奇制药技术（石家庄）有限公司 | Voriconazole composition and preparation method thereof |
| PT109117B (en) * | 2016-01-28 | 2019-02-01 | Hovione Farm Sa | COMPLEXATION OF PHARMACEUTICAL ACTIVE INGREDIENTS |
| US20190365720A1 (en) | 2016-11-18 | 2019-12-05 | Aicuris Anti-Infective Cures Gmbh | Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions |
| EP3584245A4 (en) | 2017-02-17 | 2020-08-26 | Wuhan LL Science And Technology Development Co., Ltd. | Triazole antibacterial derivative and pharmaceutical composition and use thereof |
| CN113750034A (en) * | 2020-06-05 | 2021-12-07 | 中南大学湘雅三医院 | Ear temperature-sensitive gel and preparation method thereof |
| CN116570558B (en) * | 2023-06-21 | 2023-12-26 | 广州仁恒医药科技股份有限公司 | Voriconazole ophthalmic nanometer slow-release composition and preparation method and application thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3346123A1 (en) | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
| DE3347421A1 (en) | 1983-12-29 | 1985-07-11 | Hoechst Ag, 6230 Frankfurt | METHOD FOR PRODUCING LOW FLUORINE ALKALIPHOSPHATE SOLUTIONS |
| GB8819308D0 (en) * | 1988-08-13 | 1988-09-14 | Pfizer Ltd | Triazole antifungal agents |
| KR0166088B1 (en) * | 1990-01-23 | 1999-01-15 | . | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| US5278175A (en) * | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| GB9002375D0 (en) * | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| GB9512961D0 (en) | 1995-06-26 | 1995-08-30 | Pfizer Ltd | Antifungal agents |
| GB9602080D0 (en) | 1996-02-02 | 1996-04-03 | Pfizer Ltd | Pharmaceutical compounds |
-
1997
- 1997-06-21 GB GBGB9713149.4A patent/GB9713149D0/en active Pending
-
1998
- 1998-02-06 UA UA99126910A patent/UA57083C2/en unknown
- 1998-05-05 TW TW087106918A patent/TW406023B/en not_active IP Right Cessation
- 1998-06-02 DE DE69814091T patent/DE69814091T2/en not_active Expired - Lifetime
- 1998-06-02 WO PCT/EP1998/003477 patent/WO1998058677A1/en active IP Right Grant
- 1998-06-02 ME MEP-1999-681A patent/ME00907B/en unknown
- 1998-06-02 PL PL337692A patent/PL191295B1/en unknown
- 1998-06-02 KR KR10-1999-7012034A patent/KR100372988B1/en not_active IP Right Cessation
- 1998-06-02 TR TR1999/03191T patent/TR199903191T2/en unknown
- 1998-06-02 CA CA002295035A patent/CA2295035C/en not_active Expired - Lifetime
- 1998-06-02 CZ CZ19994096A patent/CZ289570B6/en not_active IP Right Cessation
- 1998-06-02 DK DK98930793T patent/DK1001813T3/en active
- 1998-06-02 EP EP98930793.9A patent/EP1001813B8/en not_active Expired - Lifetime
- 1998-06-02 BR BRPI9809468A patent/BRPI9809468B8/en active IP Right Grant
- 1998-06-02 EA EA199900937A patent/EA001924B1/en not_active IP Right Cessation
- 1998-06-02 CN CN98806446A patent/CN1125653C/en not_active Expired - Lifetime
- 1998-06-02 AT AT98930793T patent/ATE238812T1/en active
- 1998-06-02 SI SI9830469T patent/SI1001813T1/en unknown
- 1998-06-02 JP JP11503686A patent/JP2000513029A/en not_active Withdrawn
- 1998-06-02 ID IDW991429A patent/ID22939A/en unknown
- 1998-06-02 PT PT98930793T patent/PT1001813E/en unknown
- 1998-06-02 AU AU81104/98A patent/AU724799B2/en not_active Expired
- 1998-06-02 ES ES98930793T patent/ES2195355T3/en not_active Expired - Lifetime
- 1998-06-02 IL IL13291898A patent/IL132918A/en not_active IP Right Cessation
- 1998-06-02 RS YUP-681/99A patent/RS49633B/en unknown
- 1998-06-02 HU HU0003323A patent/HU228338B1/en unknown
- 1998-06-02 NZ NZ501066A patent/NZ501066A/en not_active IP Right Cessation
- 1998-06-02 US US09/402,289 patent/US6632803B1/en not_active Expired - Lifetime
- 1998-06-02 SK SK1593-99A patent/SK282946B6/en not_active IP Right Cessation
- 1998-06-10 PA PA19988453201A patent/PA8453201A1/en unknown
- 1998-06-15 SA SA98190159A patent/SA98190159B1/en unknown
- 1998-06-17 TN TNTNSN98090A patent/TNSN98090A1/en unknown
- 1998-06-17 DZ DZ980133A patent/DZ2523A1/en active
- 1998-06-17 MA MA25117A patent/MA26508A1/en unknown
- 1998-06-18 AR ARP980102924A patent/AR015900A1/en active IP Right Grant
- 1998-06-18 AP APAP/P/1998/001268A patent/AP912A/en active
- 1998-06-19 ZA ZA9805364A patent/ZA985364B/en unknown
- 1998-06-19 HR HR980341A patent/HRP980341B1/en not_active IP Right Cessation
- 1998-06-19 UY UY25055A patent/UY25055A1/en not_active IP Right Cessation
- 1998-06-19 PE PE1998000539A patent/PE84899A1/en not_active IP Right Cessation
- 1998-06-20 MY MYPI98002792A patent/MY118151A/en unknown
- 1998-06-20 EG EG70998A patent/EG23910A/en active
- 1998-06-23 CO CO98035641A patent/CO4940450A1/en unknown
-
1999
- 1999-11-12 NO NO19995565A patent/NO313125B1/en not_active IP Right Cessation
- 1999-11-15 BG BG103882A patent/BG64584B1/en unknown
- 1999-11-15 IS IS5248A patent/IS2004B/en unknown
- 1999-12-10 OA OA9900277A patent/OA11232A/en unknown
-
2000
- 2000-11-17 HK HK00107329A patent/HK1027966A1/en not_active IP Right Cessation
-
2002
- 2002-03-27 JP JP2002088076A patent/JP5089004B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2295035C (en) | Pharmaceutical formulations containing voriconazole | |
| JP4202273B2 (en) | Inclusion compound of fumagillol derivative or salt thereof, and pharmaceutical composition containing the inclusion compound | |
| IE80461B1 (en) | New compositions containing taxane derivatives | |
| US20080318898A1 (en) | Inclusion complexes of butylphthalide with cyclodextrin or its derivatives, a process for their preparation and the use thereof | |
| JP2003063965A (en) | Cilostazol aqueous composition for injection | |
| US7259153B2 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
| CA2486571C (en) | Pharmaceutical composition | |
| EP2561863A1 (en) | Pharmaceutical compositions comprising voriconazole | |
| KR20160115827A (en) | Preparation comprising indole compound and process for preparing the same | |
| MXPA99012075A (en) | Pharmaceutical formulations containing voriconazole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180604 |